A multi-year funding boom in AI drug discovery is starting to pay off for investors through licensing deals and exits.
Between the lines: The target pool includes AI discovery tools, pathology systems and data layers with clearer operational and productivity benefits — a trend also reflected in licensing and commercial agreements.
